JERSEY, Channel Islands, July 02, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced the Board of Directors’ decision to amend Chief Executive Officer (CEO) Franz Walt’s employment agreement to be auto-renewable. The original contract was set to expire in 2020.

“Under Mr. Walt’s leadership, Quotient has consistently met its milestones and is now positioned for a successful future. The contract amendment allows us to secure the continuity in leadership which is essential for sustainable success,” said Heino von Prondzynski, the Company’s Chairman of the Board.

Mr. Walt was appointed CEO of Quotient in March 2018, and during his tenure he has developed and executed the company’s long-term strategy beginning with a successful field trial of the Initial immunohematology (IH) microarray, followed by ISO certification of the new manufacturing facility, CE mark self-certification of the MosaiQ instrument, and most recently by obtaining the CE mark for the Company’s first microarray.

Mr. Prondzynski continued, “We are delighted to have Franz at the helm as we move forward and continue to reshape the way diagnostics practiced.”

About Quotient Limited
Building on 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and operational cost savings to laboratories around the world. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania.